InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Shareholder Update 1 Jun 2011 9:10AM $0.064 $0.046 fallen by 28.13%
$15 Immuron Granted FDA pre-IND Meeting re Phase 2b Trial 19 Apr 2011 9:21AM $0.074 $0.046 fallen by 37.84%
$15 Immurons Influenza Program Shows Effectiveness in Trials 17 Mar 2011 9:10AM $0.069 $0.046 fallen by 33.33%
$15 Important Progress in HIV Prevention Project 8 Mar 2011 8:45AM $0.070 $0.046 fallen by 34.29%
$15 Immuron Granted Key Patent for Influenza Product 1 Mar 2011 10:18AM $0.075 $0.046 fallen by 38.67%
$15 Half Yearly Report and Accounts 1 Mar 2011 8:28AM $0.073 $0.046 fallen by 36.99%
$15 Australian Sales of Travelan expected to Increase 24 Feb 2011 9:57AM $0.075 $0.046 fallen by 38.67%
$15 Appointment of New Chief Executive Officer 17 Jan 2011 9:02AM $0.080 $0.046 fallen by 42.50%
$15 Preliminary Final Report 31 Aug 2010 2:51PM $0.078 $0.046 fallen by 41.03%
$15 Successful Results from NASH Clinical Trial 23 Aug 2010 8:29AM $0.100 $0.046 fallen by 54%
$15 Immuron and Nycomed expand `Travelan` into other territories 11 Jun 2010 10:03AM $0.063 $0.046 fallen by 26.98%
$15 Collaboration with Nycomed on Influenza Product 21 May 2010 9:25AM $0.067 $0.046 fallen by 31.34%
$15 Strong Interest in Immuron NASH Product 17 May 2010 10:26AM $0.066 $0.046 fallen by 30.30%
$15 Nycomed Licenses Immuron`s Travelan Product 6 May 2010 8:43AM $0.065 $0.046 fallen by 29.23%
$15 Pre-clinical Trials for Influenza Prevention Product 4 May 2010 9:08AM $0.065 $0.046 fallen by 29.23%
$15 HIV Phase 2 trial completed. Final results expected mid year 19 Apr 2010 11:38AM $0.070 $0.046 fallen by 34.29%
$15 Shareholder Share Purchase Plan 19 Apr 2010 10:04AM $0.070 $0.046 fallen by 34.29%
$15 Phase II clinical trial for Metabolic Syndrome and NASH 29 Mar 2010 11:25AM $0.077 $0.046 fallen by 40.26%
$15 Half Yearly Report and Accounts 25 Feb 2010 5:56PM $0.080 $0.046 fallen by 42.50%
$15 Commencement of Phase 2 Clinical Trials - Metabolic Syndrome 16 Dec 2009 9:17AM $0.069 $0.046 fallen by 33.33%
$15 Chairman and CEO presentations and Nycomed A`ment 23 Nov 2009 8:40AM $0.075 $0.046 fallen by 38.67%
$15 Significant Progress in Treatment of Metabolic Syndrome 11 Nov 2009 8:43AM $0.074 $0.046 fallen by 37.84%
$15 Preliminary Final Report 31 Aug 2009 3:01PM $0.057 $0.046 fallen by 19.30%
$15 Influenza Drug Development Program 13 Aug 2009 9:41AM $0.105 $0.046 fallen by 56.19%
$15 Influenza Drug Development Program 11 Aug 2009 10:38AM $0.042 $0.046 risen by 9.52%

751 - 775 of 782 results

Page 31 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.